Interested in new trials?
Get alerts for new trials in your area by subscribing now
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
What is the difference between Immunotherapy and Chemotherapy?
There is one practical difference worth knowing. Chemotherapy works while you take it. Immunotherapy trains an immune response, so some people keep responding for years after treatment ends. Oncologists call this the tail of the curve. It does not happen for everyone, and predicting who it happens to is one of the main questions current research is trying to answer.
Immunotherapy in cancer is not the same thing as allergen immunotherapy, the allergy shots and drops used for pollen or pet allergies. Both train the immune system, but they are separate fields with separate studies. This page covers cancer immunotherapy. CAR-T cell therapy is a form of immunotherapy too, and it has its own page: CAR-T cell therapy clinical trials.
Types of immunotherapy clinical trials
Checkpoint inhibitors in new cancers and earlier settings
Drugs such as pembrolizumab and nivolumab are approved in many cancers. Trials now test them in cancers where they are not yet approved, and earlier in the course of treatment, including before surgery rather than after.
Combination trials
The largest group. Immunotherapy paired with chemotherapy, radiation, targeted drugs or another immunotherapy, testing whether the combination reaches tumours that do not respond to either alone.
Predicting who responds
Immunotherapy works extremely well for some people and not at all for others, and current tests only partly explain why. Many studies collect tumour and blood samples specifically to find better predictors.
Solid tumour resistance
Some tumours suppress immune cells in the tissue around them. Trials test ways to change that environment so immunotherapy can work where it currently fails, including in glioblastoma, pancreatic and prostate cancer.
Cancer vaccines and other approaches
Including personalised vaccines built from a patient's own tumour, oncolytic viruses, and bispecific antibodies that bring T cells and cancer cells together.
Side effect and long term studies
Because immunotherapy works by loosening immune restraint, its side effects look like autoimmune conditions. Trials test ways to predict, prevent and manage them, and follow people for years afterwards.
Who can participate in immunotherapy clinical trials?
Most trials require a confirmed cancer diagnosis and a specific treatment history, often disease that has returned or has not responded to standard therapy. Many also require a biomarker test on the tumour, such as PD-L1 expression or microsatellite instability, so recent pathology results are useful to have.
Studies also check organ function, and usually exclude people with active autoimmune conditions or those taking high dose steroids, since both interact with how immunotherapy works. Eligibility always varies by study.
How long does immunotherapy take?
Checkpoint inhibitors are usually given as an infusion every two to six weeks, and treatment often continues for up to two years if it is working and tolerated. Responses are typically slower to appear than with chemotherapy, and scans early in treatment can be difficult to interpret because immune activity can make a tumour look temporarily larger before it shrinks.
Do immunotherapy trial participants get paid?
Some studies offer compensation for time and travel, and study related care, including the study drug and required monitoring, is typically provided at no cost to participants. Compensation varies by trial and is always described during informed consent before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in an immunotherapy clinical trial
Identify your trial. Use the filters to combine your diagnosis with immunotherapy. Titles name the cancer, the drug or drug class, and the setting, such as "first line" or "relapsed or refractory".
Check the location. Most immunotherapy trials run at cancer centres. Some sponsors help with travel and lodging, and the study details say so.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your exact diagnosis and stage, any biomarker testing already done on the tumour, and the list of treatments you have had and how the disease responded.
Submit the application. A study coordinator reviews it and contacts you. Nothing is decided until you have gone through informed consent, and your oncologist stays involved.